Compare Corning Incorporated (GLW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Zimmer Biomet Holdings Inc — how do they compare? Corning Incorporated trades at $156.21 (market cap $131.65B), while Zimmer Biomet Holdings Inc trades at $89.08 (market cap $16.95B). The key difference: Corning Incorporated is far larger — about 7.8× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 35 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| GLW | ZBH | |
|---|---|---|
Market Cap | $131.65B | $16.95B |
Volume | 8,992,522 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $255.79 | $103.98 |
52-Week Low | $78.03 | $79.58 |
Typical Hold Time | 35 Days | 89 Days |
Enterprise Value | $138.52B | $24.02B |
Dividend Yield | 0.73% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $155.95, down 4.45% today amid a bearish technical outlook despite strong fundamentals. The company recently secured a significant $3B+ fiber supply agreement with AT&T, boosting its optical communications segment. GLW has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Analyst consensus remains positive with a $171.25 price target, though technical indicators show selling pressure with support at $149 and resistance at $158.
GLW presents a compelling long-term opportunity with strong revenue growth projections and strategic positioning in fiber optics for AI infrastructure. However, elevated valuation multiples (P/E 70.43) and ongoing patent litigation investigations pose near-term risks. The stock's current technical weakness may offer entry points for investors bullish on the company's fiber optic expansion and AI-driven connectivity demand.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
